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1. Introduction 
The Papanicolou screen (“Pap smear”) was developed in 1928 by Dr. George Papanicolaou 
for the identification of cervical cancers. It became widely known after his publication in 
1941 and widely used in clinical practice in the 1950s; it is now the most commonly 
performed cancer screening test world-wide (1). This has been one of the most successful 
cancer screening techniques in modern medicine, and in the United States rates of cervical 
cancer have decreased by almost 80% since the 1950s (2,3). Pap smear screening has been 
widely embraced by physicians and women alike, and is considered a critical part of the 
routine health care of women. However, up to 20% of American women do not receive 
regular Pap smears, and in developing countries without the complex resources required to 
process and read Pap specimens, screening remains a challenge (4). Among women with 
cervical cancer in the U.S., at least 60% did not have appropriate Pap surveillance prior to 
their diagnoses (5). 
In the decades since the initial development of the Pap smear, our understanding of the 
pathophysiology of cervical cancer has evolved considerably. The occurrence of pre-
malignant cervical lesions, now referred to as cervical dysplasia, was recognized as early at 
the 1940s (6). During the 1970s and 1980s, the human Papilloma virus (HPV) was identified 
within cervical lesions (7, 8). As early as 1976, Dr. Harald zur Hausen and colleagues 
postulated a role for the HPV in cervical oncogenesis, and his subsequent work isolating 
oncogenic HPV strains and elucidating the oncogenic process earned him the Nobel Prize in 
Medicine in 2008 (9-11).  
The discoveries of premalignant cervical lesions and the role of HPV in cervical dysplasias 
and cancers have also enabled physicians to gradually refine the use of Pap smear screening. 
As a result, the number of women who need Pap smears, and the frequency at which they 
are recommended, has changed significantly over the last several years. However, 
dissemination of the newest guidelines has been met with some resistance both from 
women and their physicians.  
In this article, we will review these advancements and the current evidence about the 
modern use of Pap smears and HPV screening, the evidence leading to the new 
recommendations and some barriers to their full implementation. 
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2. Fundamentals of screening for disease 
Screening can be defined as the effort to identify asymptomatic disease or disease precursors 
through examinations or tests applied rapidly to an appropriate segment of the population. 
Screening tests delineate patients who appear well and have a disease from those who do 
not have a disease. Numerous examples of screening tests exist in clinical practice as a part 
of primary or secondary prevention, including blood pressure measurements, serum 
cholesterol measurements, pap tests, and colonoscopy. Importantly, screening tests are not 
intended to be diagnostic. A positive screening test requires follow-up and commitment to 
further investigation.  
A successful and appropriate screening test depends on numerous criteria, which cluster in 
to three general categories delineated by Katz: disease-specific criteria, test-specific criteria, 
and society or system-criteria (Table 1) (12). All of the factors listed in Table 1 impact the 
potential benefits of screening programs both to individual patients and populations. 
Disease screening would be unjustified if the burden of disease is insignificant or if 
treatment outcomes are no different between asymptomatic cases diagnosed at an early 
stage and symptomatic cases diagnosed at later stage. If an effective treatment for a disease 
is not available, screening and early detection confers no benefit to patients. Disease 
prevalence, discussed in detail below, is integral to screening programs as screening for 
extremely rare conditions would not be cost-effective or accurate given that false-positive 
tests may outnumber true-positive results. The screening test itself must be convenient, 
acceptable, safe, and cost-effective for patients. An ideal screening test should take only a  
 
Disease-specific 
 Condition must have significant burden on health (morbidity, mortality, suffering) 
 Disease detectable in asymptomatic state 
 Natural history of disease modifiable with treatment 
 Early, effective treatment available 
 Appropriate prevalence: not too rare or too common 
Test-specific 
 Highly sensitive to reliably identify disease cases 
 Highly specific to minimize false positives 
 Cost-effective 
 Test is safe, convenient, and acceptable to patients 
Society/System-specific 
 Confirmatory, diagnostic testing readily available for screen positive 
 Effective treatment readily available for confirmed cases 
 Screening program cost-effective for population 
Adapted from Katz DL, Fundamentals of screening: the art and science of looking for trouble, Sage 
Publications, London, 2001 (reference 12).  
Table 1. Characteristics of an Appropriate Screening Test 
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few minutes to perform, require minimal preparation by the patient, and be inexpensive. 
Additionally, given that screening programs require a significant commitment of resources, 
they should be cost-effective and confer benefit on a population or societal level. As 
described further in this chapter, screening for cervical cancer exemplifies an ideal screening 
test by meeting all of the aforementioned criteria. 
Importantly, a successful screening program is dependent upon the various characteristics 
of the screening test, and an understanding of these principals is fundamental to providers 
and public health officials. Sensitivity and specificity are characteristics inherent to a test 
and are independent of disease prevalence. Sensitivity is the probability that if the disease is 
present, the test is positive. Mathematically, the numerator is the number of subjects with a 
disease who have a positive test and the denominator is the total number of subjects with a 
disease. A test with high sensitivity effectively identifies subjects with disease and 
infrequently misses true cases (low false negative rate). Specificity is the probability that if a 
disease is absent, the test is negative. Mathematically, the numerator is the number of 
subjects without a disease who also have a negative test, and the denominator is the total 
number of subjects without disease. Tests with high specificity infrequently identify subjects 
as having disease when they do not (low false positive rate). Given that screening tests must 
identify disease in asymptomatic patients where the prevalence is usually low (even in high 
risk groups), a good screening test must have high sensitivity as to not miss the few cases of 
disease present. Additionally, the sensitivity must remain high in the early stages of disease. 
A test that demonstrates high sensitivity only in late-stage disease, where treatment may be 
less effective, will not provide clinical utility. Good screening tests should also have high 
specificity to reduce the number of false positive results which require follow-up evaluation 
or intervention.  
The calculation of sensitivity and specificity for screening tests are determined in a manner 
similar to that of diagnostic tests, however one major difference deserves mention. The 
sensitivity and specificity of diagnostic tests are based on comparisons between the test 
results and a different test (the reference or “gold standard”). For a screening test, the “gold 
standard” for detecting disease includes both another test and a period of follow-up. 
Additional testing is routinely administered to those who have positive screening tests for 
confirmation (differentiation of true and false-positive results). However, a period of follow-
up is necessary for all negative results to differentiate subjects with true and false-negative 
tests. This characteristic is particularly important in cancer screening, where cancers 
discovered during the period of follow-up (interval cancers) occur. Choosing the 
appropriate duration of follow-up may impact the sensitivity and specificity of the test, 
which overestimates sensitivity if the follow-up period is too short and underestimates 
sensitivity if the follow-up period is too long. (13) 
Positive and negative predictive values (PPV, NPV) also represent important characteristics 
of screening tests. PPV represents the probability that a subject with a positive test has a 
disease. The numerator is the number of subjects with disease who have a positive test and 
the denominator is the number of subjects with a positive test. Conversely, NPV represents 
the probability that subject with a negative test does not have disease. The numerator is the 
number of subjects without disease who have a negative test and the denominator is the 
number of subjects with a negative test. The predictive values depend on disease prevalence 
within a population. For a test with a given sensitivity and specificity, as prevalence rises 
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the PPV of a test increases and the NPV decreases. Conversely, as prevalence falls, the PPV 
decreases and the NPV increases. This observation has important implications for screening 
tests, where the disease prevalence is generally low. Therefore, most screening tests have 
low PPV and high NPV (despite high sensitivity and specificity). Clinically, this implies that 
providers offering screening tests to their patients must accept the fact that many patients 
will screen positive and not truly have disease; however, these patients still require follow-
up evaluation and testing.  
3. Biases and pitfalls of screening programs 
Instinctively, screening for disease has apparent benefits. However, given that no test in 
medicine is perfect, widespread adoption of screening tests prior proving their benefit can 
become problematic. Therefore, prior to implementing population-wide screening 
programs, a test should be subject to careful study. Similar to any intervention in medicine, 
the most rigorous means of establishing the efficacy of a treatment or intervention is with a 
randomized controlled trial. However, many years and large numbers of patients are 
required to establish the efficacy of a preventative intervention or screening test. For 
example, a study demonstrating that early treatment of colorectal cancer detected by disease 
screening reduced cancer-related mortality by one-third required 45,000 subjects and 13 
years of follow-up surveillance (14). Therefore, a case series describing screening programs 
or a “clinical impressions” of the impact of screening do not suffice to establish efficacy.  
Rigorous study is necessary to avoid biases specific to the study of screening programs. One 
such bias, lead-time bias, occurs when discovering a disease in an early stage with screening 
does not impact mortality rates or outcomes relative to discovering the disease later when it 
would typically present with symptoms. Discovering the disease early may appear 
beneficial by increasing “survival time”. However, in reality, early detection only serves to 
advance diagnosis, thereby increasing the duration of time a patient has a disease. A patient 
living with disease for a longer period of time may be subject to more frequent examinations 
and tests as well as increased anxiety from a longer time with knowledge of disease.  
Another type of bias present in screening programs is length-time bias. Length-time bias is a 
type of selection bias that occurs when outcomes appear better in a screened population of 
subjects due to the fact that diseases with a favorable prognosis are more readily discovered 
with screening. This phenomenon is exemplified by cancer screening, where slow-growing 
lesions are diagnosed more readily than rapidly-growing lesions due to a longer pre-clinical, 
asymptomatic period. Given that slow-growing tumors generally have a better prognosis 
than rapidly-growing tumors, screening programs generally discover slow-growing tumors 
with inherently more favorable prognoses. Therefore, while mortality rates for cancers 
discovered through screening may be more favorable, screening is not truly protective in 
this setting.  
Lastly, compliance bias can occur in studying the efficacy of screening programs. 
Compliance, the degree to which patients follow or adhere to medical advice, may impact 
studies of disease screening as compliant patients tend to have better prognoses 
independent of screening. For example, studies that compare disease outcomes between 
subjects who volunteer for screening and those that do not may demonstrate improved 
outcome, however this improvement may be secondary to higher compliance amongst 
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volunteers rather than any benefit conferred by the screening program. Therefore, to 
effectively evaluate the impact of any screening test or program, randomized trials with 
concurrent screening and control groups must be conducted to minimize the introduction of 
length-time and compliance bias. By following studied populations with mortality rates, 
rather than survival rates, lead-time bias can be avoided.  
Screening programs also have the potential to produce significant adverse effects in a 
screened population, which highlights another critical reason to rigorously study screening 
tests prior to their widespread application. Adverse effects range from discomfort produced 
from the test itself to false-positive test results to overdiagnosis. In effective screening 
programs, false-positive results account for a minority of all test results. However, false-
positive results can still have a substantial impact on a large number of patients by 
producing anxiety and the discomfort and cost of additional follow-up tests. Given that 
screening tests are often repeated in intervals, each repeat screen is subject to further false-
positive results. Additionally, the negative impact of overdiagnosis cannot be overstated. 
While the underlying presumption in cancer screening is that earlier detection translates 
into improved outcomes, recent evidence has challenged this thesis. In a recent editorial, 
Welch reviewed the impact of a 10-year course of screening mammography on 2500 women 
in the US at age 50 (15). While one breast cancer-related death would be prevented by 
mammography, up to 1000 women will have at least one false-positive result and 
approximately half will undergo a breast biopsy. Additionally, breast cancer will be 
overdiagnosed in 5-15 women who will be treated “needlessly” with surgery, 
chemotherapy, radiation, or a combination thereof. Therefore, even excellent screening tests 
are not without pitfalls.  
Screening for cervical cancer exemplifies a good screening test by satisfying the 
aforementioned criteria described by Katz (Table 1). Cervical cancer is appropriately 
prevalent and has a significant disease-related morbidity and mortality. The natural history 
of the disease, from HPV infection to carcinoma, has been clearly established. A 
premalignant window for intervention exists such that treatment significantly decreases 
disease burden. Follow-up testing with colposcopy is generally available and effective at 
detecting premaligant lesions. Excision procedures reliably treat premalignant lesions and 
prevent progression to cancer. When utilized for screening, Pap smears have acceptable test 
characteristics. While reports of sensitivity and specificity vary significantly between 
studies, a meta-analysis demonstrated sensitivity as high as 86% and specificity as high as 
100% (16). Additionally, negative predictive values have been demonstrated to be higher 
than 95% (17). As such, Pap screening remains one of the most significant and successful 
screening tests in the history of modern medicine. The remainder of this chapter provides 
and evidence-based assessment of Pap and HPV screening with a discussion current 
recommendations and controversies. 
4. History of Pap screening and impact of screening on cervical cancer 
incidence and mortality 
Dr. George Papanicolaou, a physician and scientist trained in Greece in the early 1900s, 
immigrated to the United States in 1913 seeking greater opportunities in medicine and 
research (Figure 1). He became acquainted with T.H. Morgan, a well-known zoologist who 
had already read and cited Papanicolaou’s doctoral thesis in a publication. Mr. Morgan 
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Adapted from Vilos G. Dr. George Papanicolaou and the Birth of the Pap Test. Obstetrical & 
Gynecological Survey. 54(8):481-483, August 1999. 
Fig. 1. Dr. George Papanicolaou 
recommended Papanicolaou for a part time position as a technician in the pathology 
department at New York Hospital. His scientific mind impressed the department and 
shortly thereafter he was appointed as an assistant professor in the anatomy department at 
Cornell Medical School. His research on the chromosomal basis of gender differentiation in 
guinea pigs led to the discovery that exfoliated cells from the vagina could predict the 
timing of ovulation. In his initial experiments, he used a small nasal speculum to obtain the 
sample and then plated slides for microscopy, noting “an impressive wealth of diverse cell 
forms and a sequence of distinctive cytologic pattern” (21). With this observation, he 
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hypothesized that an analogous pattern could be appreciated in humans. Concomitantly, he 
began to obtain samples from his wife for further study, which represented the birth of the 
Pap smear. Shortly thereafter, he initiated the systematic study of exfoliated vaginal cells in 
women working at New York Hospital. In February 1295, he encountered a woman with an 
undiagnosed carcinoma of the cervix. The slide produced from her sample was recognized 
as cancer, and he then understood the implications of his methods on the diagnosis of 
cervical cancer. He confirmed his findings by recruiting other women with known 
cervical cancers and characterizing their cervicovaginal samples. He presented his test 
and findings at the Third Race Betterment Conference in Battle Creek, Michigan in 
January of 1928 (22).  
Papanicolaou’s 1928 presentation was greeted with skepticism by pathologists at the time as 
they felt biopsy should remain the gold standard diagnostic modality. Unfortunately, ten 
additional years of research was required before the Pap test was evaluated rigorously as a 
potential diagnostic tool. Finally, in 1939, at the urging of his department chair, 
Papanicolaou and fellow gynecologic pathologist Herbert F. Traut initiated a clinical trial of 
the Pap test. Vaginal samples were collected from all women admitted to the obstetric and 
gynecologic services at New York Hospital. They published their findings in the American 
Journal of Obstetrics and Gynecology in 1941, which detailed the differences between normal 
and malignant cells of the cervix. In this landmark publication, Papanicolaou proposed his 
technique as a simple, inexpensive means to test large numbers of women and diagnose 
cancer at an earlier stage which would be more amenable to treatment (1).  
Shortly after the publication of this manuscript, his technique started to gain more 
widespread acceptance including the support of the National Cancer Institute and the 
American Cancer Society (ACS). In 1948, the ACS held the first interdisciplinary conference 
to promote the “Pap” test (23). In the late 1940s and early 1950s, community-based projects 
were undertaken to explore the feasibility and acceptance of screening large proportions of 
the population as well as to evaluate the impact of screening on cancer incidence and 
mortality. Screening programs in Ohio, Tennessee, and Kentucky all demonstrated increases 
in the detection of carcinoma in situ and decreases in the incidence of invasive carcinoma. 
For example, in the study from Kentucky, over 90% of the female population in the greater 
Louisville area was screened at least once during an 11 year period and the rate of cervical 
cancer declined by 32% (24-26).  
With local and regional programs demonstrating benefit, the ACS promoted a national 
effort and campaign for screening. In 1957, the ACS initiated a campaign for annual, 
universal screening called the “Uterine Cancer Year”. The American College of Obstetricians 
and Gynecologists followed with recommendations for cervical cytologic screening in their 
first and second editions of the Manual of Standards in Obstetric-Gynecologic Practice, 
published in 1959 and 1965 respectively (27). At that point, the framework was in place for 
the incorporation of Pap screening into standard gynecologic practice.  
The aforementioned community-based evaluations established that cervical cytologic 
screening was acceptable to large populations of women. Importantly, these evaluations 
also demonstrated a consistent decrease in cervical cancer incidence and mortality in each 
community where screening was introduced. Interestingly, however, no randomized clinical 
trials of cervical cytology assessment with Pap screening have been performed to date. 
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Therefore, while a true causal relationship may never be formally established, a consistent 
association of screening with a reduction in cervical cancer burden provides convincing 
evidence of the impact of the Pap test.  
The international epidemiology of cervical cancer further supports a direct correlation 
between screening programs and decreased cancer incidence and mortality. Prior to the 
widespread adoption of screening programs in developed countries, incidence rates of 
cervical cancer were similar to those found in developing countries today (28). Currently, 
however, marked disparities exist between the incidence of cervical cancer as well as 
cervical cancer-related mortality between the developed and developing world (Figure 2). 
Due to widespread implementation of cervical cancer screening programs in the developed 
world, cervical cancer has become one of the least common malignancies impacting women. 
In the United States in 2007, approximately 12,000 women were diagnosed with cervical 
cancer and 4000 died from the disease. Additionally, as noted by the NCI Surveillance 
Epidemiology and End Results (SEER) data, the incidence and mortality rate for cervical 
cancer continues to decline at 2.6% per year and 0.6% per year respectively (data available 
through 2008) (29, 30). Worldwide, however, the incidence of cervical cancer is 
approximately 500,000 cases per year with over 250,000 cancer-related deaths (31). 
According to the World Health Organization, over 80% of cervical cancer-related deaths 
occur in the developing world, and the lack of access to screening and prevention programs 
represents the primary reason for the enormous disparity between resource-rich and 
resource-poor nations  (32). Additionally, even in countries with adequate screening programs, 
poor women suffer a disproportionate share of the burden of disease, with incidence rates  
 
Adapted from: Sankaranarayanan R, Ferlay J. Worldwide burden of gyaecological cancer: the size of the 
problem. Best Pract Res Clinc Obstet Gynaecol. 2006;20:207-225. 
Fig. 2. Age-standardized incidence rates of cervical cancer per 100,000 women 
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approximately two-fold higher than more affluent women (28). Cervical cancer does not 
make the list of the ten most incident or lethal cancers in the United States. However, 
cervical cancer remains the second leading cause of cancer-related female mortality 
worldwide (29, 32). It is therefore a substantial public health challenge despite the presence 
of an effective screening test. Moving forward, resources must be allocated for the 
development of comprehensive screening programs as well as HPV vaccination programs in 
the developing world. 
5. HPV as the causative agent for cervical cancer 
Human Papilloma viruses (HPV) were first identified in cervical cancer cells in 1947 by 
Pund et al, who noted “koilocytic changes” in cervical tissues (6). Subsequently, multiple 
investigators have elucidated that infection with HPV is the critical factor in cervical 
oncogenesis (7-11). There are over 120 strains of HPV, and approximately 30 strains affect 
the anogenital region (33). These are classified as either “low risk” or “high risk” HPV 
subtypes. Low risk HPV subtypes include 6, 11, 40, 42 and 43 and are associated with genital 
warts, but not significantly associated with cervical cancer. High risk HPV subtypes include 
16, 18, 31, 33, 35, 39, 45, 51, 52, 56 and 58; these are associated with cervical dysplasia and 
cancer. HPV 16 accounts for approximately half of squamous cervical cancers, HPV 18 for 
another 10-15%, and 31, 33, 35, 52 and 58 about 2-5% each. Overall, between 95-100% of 
squamous cervical cancers are HPV-related (34, 35). 
HPV is a family of double-stranded, circular DNA viruses. The genome codes for two 
oncogenic proteins, E6 and E7, that interfere with control of host cell replication. The E6 
protein binds to the tumor suppressor gene, p53, and inactivates it. The E7 protein binds to 
the Rb tumor suppressor gene which results in loss of apoptosis and cell-cycle control. This 
leads to unchecked replication of infected cells, and shedding of the virus which can be 
passed on to new hosts. Episomal replication can lead to destabilization of host genome and 
aneuploidy, which in turn may promote integration of the HPV genome in fragile areas of 
the host DNA. Integration of HPV DNA into the host cell DNA is associated with cervical 
dysplasias and cancer. 
HPV is transmitted by sexual contact, and in fact is the most common sexually transmitted 
infection in the world. Population-based studies have found that the lifetime prevalence of 
HPV infection is 50-80% (35). The estimated attack rate after contact with an HPV-infected 
partner is 66% (34). However, over 75% of HPV infections are asymptomatic, and are 
cleared by the host immune system within 6-24 months without clinical sequelae (34, 36-39). 
Most of these infections are not evident to the patient and are never detected before they are 
cleared. For patients with HPV that is clinically detected, approximately 70% will 
demonstrate viral clearance within one year, and 90% within two years. Importantly, it is 
persistent infection with high risk HPV that is associated with progressive cervical dysplasias 
and cervical cancer. 
Screening for cervical cancer consists of cytologic screening—the Pap smear—either alone or 
in conjunction with HPV testing. In the following sections we will review screening 
strategies and the current recommendations for the use of both Pap smears and the available 
HPV tests.  
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6. Pap smear screening strategies 
Pap smear screening has been considered an integral part of well-woman care for over 50 
years, and both physicians and women have incorporated it into their annual routines. 
Because of the recognition that sexual debut put women at risk for HPV, older guidelines 
recommended starting Pap smear screening at coitarche, or by age 18 if coitarche had not 
occurred. Pap smears were performed annually throughout a woman’s life, without a 
recommended terminus. A better understanding of the epidemiology and time course of 
HPV infection has allowed these long-standing recommendations to be gradually modified, 
in order to minimize unnecessary testing.  
6.1 Adolescents and young women 
When considering younger women, two points are important to bear in mind. The first is 
that the interval between HPV infection and a clinically detectable cervical dysplasia is 
months to several years. The second is that HPV is highly prevalent (up to 80%) and usually 
transient (without clinical sequelae) (34, 36, 39, 40). Understanding the time course initially 
led to an updated recommendation that women should start Pap smear screening three 
years after coitarche or by age 21. However, a finer understanding of both points together 
implies that detection of minor abnormalities in very young women is probably clinically 
irrelevant, because they nearly always resolve. Only 1 of 1000 women diagnosed with 
cervical cancer in the United States are under the age of 21, or approximately 10-12 women 
per year nationwide (41). Thus, current guidelines from the multiple American College of 
Obstetrics and Gynecology (ACOG) have been simplified to recommend initiation of Pap 
smear screening at age 21, regardless of the timing of sexual debut (40). 
Between the ages of 21 and 29, two different possible screening strategies are recommended. 
Currently, ACOG recommend biennial screening for these women. The American Society 
for Colposcopy and Cervical Pathology (ASCCP), ACS and the United States Preventative 
Services Task Force (USPSTF) have recently released draft consensus guidelines which 
recommend Pap smear screening every 3 years in this age group (40, 42, 43). 
6.2 Adult women 
Starting at age 30, the recommended interval for Pap smear screening can be extended, 
assuming several criteria are met. First, healthy women who have reached age 30 and have 
had three prior consecutive normal Pap smears can then extend their Pap screening interval 
to every three years. Second, women who have a normal Pap smear and a negative high risk 
HPV test can then be screened every three years (see additional information in “HPV 
Screening Strategies”, below). Women in either group are unlikely to develop a clinically 
significant dysplasia during the two unscreened years, and the resultant decrease in 
unnecessary Pap smears should translate into a significant savings to the health care system 
(40, 42). 
There are several important caveats to extended interval screening. First, it is key that 
women are educated about the rationale for extended interval screening, and that they 
understand that their “annual exam” consists of more than their Pap smear. Women should 
be encouraged to have a regular physical examination even in the years when a Pap is not 
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indicated. Second, there are a number of exclusion criteria for extended interval screening. 
Women with a history of moderate to severe cervical dysplasia (grades 2 or 3) are not 
eligible for this extended interval; they should continue annual Pap smears for at least 
twenty years after treatment. Other women who should continue to have annual screening 
include women exposed to diethylstilbesterol (DES), women on immunosuppressant 
medication, and women living with HIV/AIDS. Women who have a history of cervical 
cancer must continue to be screened with Pap smears indefinitely. In contrast, women who 
have undergone hysterectomy (with removal of the cervix) for reasons other than cervical 
dysplasia or cervical cancer do not need any further Pap smears postoperatively. 
Pap smear screening can be stopped between the ages of 65 or 70, depending on the source 
of the guidelines: ACOG recommends cessation between 65 and 70, and the 
ASCCP/ACS/USPSTF draft guidelines recommend cessation of Pap testing by age 70. 
Termination of Pap smear screening also requires that women meet the exclusion criteria 
noted above—that at least 20 years have passed since a moderate or severe cervical 
dysplasia, and no significant immunosuppression. Importantly, while the peak incidence of 
cervical cancer among Caucasian women is in the 40s, it is in the 70s for Hispanic and Asian 
women, and increases throughout the lifespan for African American women. Therefore, it is 
important that prior history and screening be taken into account prior to discontinuing Pap 
smears (40). 
Women often have some anxiety about stopping Pap smears, as they may fear that a cancer 
will be missed, or that their physicians are “abandoning” important screening practices 
simply because they are “too old.” It is helpful to explain that the Pap smear screens only for 
cervical cancer, and that they will still have annual gynecologic exams to screen for ovarian 
cancer and other pathology. 
7. HPV screening strategies 
Screening tests for HPV have been available since 1999. Tests exist for both low risk and 
high risk HPV; however, since low risk HPV is not associated with carciongenesis, there are 
currently no clinical indications for low risk HPV testing. Some authors have even called for 
the low risk test to be removed from the market, as it does not appear to add any clinically 
useful information, and may contribute to confusion among clinicians about how and when 
to screen for HPV (44, 45). For high risk HPV subtypes, there are three currently available 
and FDA-approved tests; the best studied of these is Hybrid Capture, and further data are 
needed to assess the reliability of newer tests (46). 
7.1 Reflex HPV testing for ASC-US Paps 
Clinically, several strategies for using HPV tests have been employed. The first and most 
prevalent use of the HPV test is for the evaluation of a non-diagnostic Pap smear. 
Approximately 4% of Pap smears will result in a reading of “atypical squamous cells of 
undetermined significance,” or ASC-US (47). These Paps may represent a wide spectrum of 
problems: non-specific inflammation, dysplasia of any severity, cervical cancer, or simply 
artifact. Further evaluation is therefore warranted; in 20-60% of women with an ASC-US 
Pap smear, dysplasia is present. The American Society for Colposcopy and Cervical 
Pathology (ASCCP) offers three management strategies: a repeat Pap smear in six months, 
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an immediate colposcopic examination of the cervix, or HPV testing. If an HPV test is 
performed and is negative, the Pap is considered normal, and the woman can simply have a 
Pap in one year. If HPV testing is positive, then the suspicion for dysplasia is higher and 
colposcopy is recommended (48). Thus in the setting of ASC-US, a negative HPV test will 
reassure those women at low risk for dysplasia and allow them to avoid unnecessary 
procedures, and a positive HPV test will ensure that women at higher risk for dysplasia are 
rapidly evaluated. For clinicians using liquid-based cytology, the HPV test can be done on 
the same sample as the Pap smear, thus obviating the need for the patient to return for a 
second exam if ASC-US is found. 
7.2 Automatic HPV testing 
The other testing strategy is “automatic” HPV testing (rather than reflexively in response to 
the cytologic result), and is appropriate for women over the age of 30. It is important that 
women under 30 years of age not undergo routine or automatic HPV screening, as the 
prevalence of HPV among younger women is very high, and most of these infections are 
transient and without consequence. Among women over 30, however, transient HPV 
infections are less common, and the HPV test has a higher positive predictive value for 
cervical dysplasia (48). 
When a woman over 30 has a cytologically normal Pap smear and a negative high risk HPV 
test, she is considered very low risk for cervical dysplasia and cancer, and should thereafter 
receive Pap smears only every three years (40, 48). Even if a woman acquires an HPV infection 
during that three year interval, the long incubation time between HPV acquisition and 
development of significant dysplasia means that her next Pap smear should still detect any 
new dysplasia in its early stages. 
When a woman over 30 has a cytologically normal Pap smear and a positive high risk HPV 
test, current guidelines recommend repeating both tests in 12 months, as it is only persistent 
HPV infection that leads to dysplasia. If at 12 months the HPV test is persistently positive, or 
if a cytologic abnormality has developed in that interval, then colposcopy is recommended 
(48). 
8. HPV vaccination 
There are currently two commercially available prophylactic vaccines against HPV: a 
quadrivalent vaccine against strains 6, 11, 16, and 18, and a bivalent vaccine against 16 and 
18. Neither vaccine has been studied long enough nor in a large enough number of women 
to demonstrate a reduction in cervical cancer among vaccines. However, both vaccines have 
demonstrated excellent immunogenicity against the targeted HPV strains, and have shown 
efficacy at reducing the surrogate endpoints of grade 2 and grade 3 cervical dysplasia (49-
51). It is anticipated that high uptake of the vaccine will reduce the number of women 
requiring colposcopy and subsequent extirpative procedures, and ultimately reduce cervical 
cancer rates. However, several caveats must be added. 
First, as vaccination protects against only two oncogenic strains, women remain vulnerable 
to other (non-vaccine) HPV strains, and therefore remain at some risk for cervical dysplasia 
and cancer. Both vaccines induce some cross-protection against non-vaccine strains, though 
this is far from perfect. Therefore, vaccinated women should continue to undergo Pap 
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smears at the interval appropriate for their age and health status—the vaccine does not 
abrogate the need for Pap smears (40). 
Second, availability and uptake of the vaccine has thus far been low for a variety of reasons. 
At present, approximately 37% of eligible girls in the United States have been vaccinated 
against HPV (52). There have been multiple barriers to its widespread adoption. These 
include parental uncertainty about the importance and timing of vaccinating young girls for 
a sexually transmitted disease, expense of the vaccine series, and even political posturing 
over the vaccine, to name a few. With widespread adoption, vaccination against HPV 16 and 
18 has the potential to eliminate up to two thirds of cervical cancer worldwide (53). The 
highest burden of HPV disease and cervical cancer clearly lies in developing nations 
without easy access to cervical cancer screening. At present, the cost of the vaccine is such 
that it is not available to the populations most in need. 
9. Barriers to adoption of evidence-based Pap smear screening 
While the current Pap smear screening guidelines have been widely publicized and received 
considerable attention in the lay press when released, there remains ongoing evidence of 
Pap smear over-use by clinicians (44, 45, 54). There are a number of barriers to physician 
compliance with evidence-based treatment protocols. These include lack of awareness of the 
guidelines, lack of “buy-in” to the new recommendations, and inertia. In addition, patient 
expectations for an annual Pap smear may drive some Pap overuse, as it may be easier to 
accede to the patient’s request than to spend limited visit time explaining HPV and the 
rationale for the new screening intervals. However, Pap smears performed too frequently or 
too early and HPV tests performed at inappropriate ages or intervals represent a significant 
cost to the health care system. Furthermore, there is the potential for patient harm when Pap 
smears are not performed according to current standards. For example, the diagnosis of 
HPV or a low grade dysplasia in an 18 year old woman may cause her real emotional 
distress, may result in her subjection to additional procedures such as colposcopies and 
biopsies, and possibly extirpative procedures. However, the 18 year old is likely to simply 
clear her HPV infection without intervention. By age 21, when her first Pap smear is due, 
one of two things will occur—she will have cleared her HPV, and her Pap smear will be 
normal, or she will have persistent dysplasia, in which case she merits further evaluation. 
The probability that she will have a cervical cancer is, as noted above, vanishingly small 
(41). 
10. Areas of controversy and uncertainty 
10.1 HPV triage: molecular screening for cervical cancer 
As demonstrated in a large international study, the prevalence of HPV among documented 
cervical cancers was over 99%, which represents the largest attributable fraction ever 
identified for a cause of cancer (55). Therefore, significant interest exists in utilizing HPV 
testing as a primary screening modality. Several large clinical studies have been conducted 
to evaluate the efficacy of primary HPV screening and/or cotesting with conventional 
cytology. The Canadian Cervical Cancer Screening Trial evaluated the test characteristics of 
HPV testing with conventional cytology in 10, 154 women aged 30-69 who underwent both 
tests. Consistent with prior studies, the sensitivity of HPV testing for the detection of CIN 2 
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or greater was significantly higher than that of conventional cytology (96.4% versus 55.4%) 
and the specificity was lower (94.1% versus 96.8%) (27, 56, 57).  
A population-based screening study in Amsterdam randomly assigned approximately 
17,000 women to either cytology/HPV co-testing or cytology alone at an initial screen. These 
women were then followed with cytology/HPV co-testing at 5 years (the standard screening 
interval in the Netherlands). Results of CIN 3 or worse were detected in 70% more women 
in the group undergoing cytology/HPV co-testing at initial screening, and women in this 
group were less likely to have CIN3 or worse detected at the five year follow-up screening 
test. Overall, the number of cases of CIN3 lesions or cancers did not differ between trial 
arms, suggesting that initial co-testing may detect significant lesions earlier but not any 
more effectively than conventional cytologic screening (58). Similar results were obtained in 
a large study conducted in England (59).  
A recent randomized controlled trial from Italy that evaluated conventional cytology 
compared with HPV DNA testing in over 47,000 women provides additional information 
regarding the efficacy of HPV screening as a primary modality (60). In this study, initial 
screening with HPV DNA testing reduced the number of invasive cervical cancers 
discovered at a second round of screening (0 cases with HPV screening, 9 cases with 
conventional cytology). Additionally, women screened with HPV testing were noted to have 
an excess number of cases of CIN 2 or greater over the two rounds of screening. Therefore, 
this study represents the first evidence that primary screening with HPV testing decreases 
the incidence of cervical cancer with earlier detection. However, HPV testing also leads to 
the overdiagnosis of women with CIN 2 or worse lesions that would have spontaneously 
regressed without treatment.  
Lastly, a long-term prospective cohort study of over 330,000 women in a Northern California 
health-maintenance organization has provided interesting new data on the safety and efficacy 
of cytology/HPV cotesting. This study demonstrated that patients with an initial negative 
HPV test demonstrated an extremely low risk of CIN3 or worse over the subsequent 5 years. 
The risk was practically equal for those with negative and ASCUS cytologies and a negative 
initial HPV test. Notably, the cumulative 5-year risk of cancer was lower in those with negative 
HPV tests compared with negative cytology at the initial screen (3.8 per 100,000 compared 
with 7.5 per 100,000). The authors concluded that a single negative HPV test is sufficiently 
reassuring against a 5-year risk of cancer. They also advocated for a triage strategy of primary 
HPV testing with positive results undergoing triage by cytology (54).  
While findings from these (and many other) studies vary in magnitude, consistent 
observations are noteworthy. Compared with cytology, HPV testing offers a highly 
reproducible, objective outcome that is easily monitored. Compared with cytology alone, 
HPV testing is more sensitive, less specific, and has a higher negative predictive value (27, 
56, 57). The lower sensitivity relative to conventional cytology is significant in that with 
primary HPV screening, significantly more women would be recommended for unnecessary 
colposcopies for transient HPV infections, which would consume substantial health care 
resources. This phenomenon is particularly true for women under age 30, who have the 
highest incidence of HPV infection and the lowest rates of cervical cancer. The addition of 
HPV testing to conventional cytology may result in the earlier diagnosis of high grade 
lesions or cancer and may reduce the incidence of caner (evidence from one clinical trial), 
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however a mortality benefit has not been demonstrated to date. Thus, additional study 
regarding the optimal screening strategy is required.  
10.2 Visual inspection with acetic acid and “Screen and Treat” programs 
Historically, visual inspection of the cervix without magnification was the initial screening 
test for cervical cancer. Introduced by Schiller in the 1930s, the test was initially performed 
by applying Lugol’s iodine to the cervix (61). The test was rapidly replaced by Pap testing, 
which demonstrated improved specificity. However, visual inspection of the cervix, after 
the application of either acetic acid or Lugol’s solution, remains a mainstay of cervical 
cancer screening in resource-poor settings given that the technique requires little equipment, 
provides rapid results, and is economical.  
A substantial body of literature exists supporting the efficacy of visual inspection techniques 
and “screen and treat” protocols. Regarding test characteristics, observational studies have 
evaluated the sensitivity and specificity of visual inspection, which were noted to be 79% 
and 85% respectively in a meta-analysis of 11 of the higher quality studies (62). The efficacy 
of visual inspection as a part of “screen and treat” programs has also been evaluated in a 
number of studies. A large randomized controlled trial in India that evaluated over 80,000 
women assigned to either triage with visual inspection followed by cryotherapy or excision 
versus standard therapy (health education). The visual inspection protocol decreased 
cervical cancer incidence and mortality (63). Additionally, a large randomized trial from 
South Africa evaluated the efficacy of two distinct screen and treat protocols in 6500 
previously unscreened women. All women in the trial were screened with visual inspection, 
HPV testing, and cytology and were then randomized to one of three treatment arms: 
cryotherapy for positive HPV test, cryotherapy for positive visual inspection, or delayed 
evaluation (follow-up at 6 months). At the 6 and 12 month follow-up colposcopic 
evaluations, significantly fewer women were noted to have CIN 2 or worse in the HPV and 
visual inspections groups compared with conventional cytology (64).  
Therefore, while conventional screening programs remain the backbone of cervical cancer 
prevention, visual inspection and screen and treat protocols provide options for women in 
low-resource settings where screening programs remain unavailable. These protocols 
provide opportunities for efficient, safe, and effective treatment of women and eliminate any 
potential problems related to communication barriers and non-compliance with follow-up. 
Additional research and resources must be directed toward the evaluation and 
implementation of effective screening and treatment protocols in low-resource settings.  
10.3 Conventional Pap screening versus liquid-based cytology 
With “conventional” Pap screening, cells obtained from the cervix are transferred directly to 
a glass slide with fixation by either ethyl alcohol or other spray fixative. Liquid-based 
cytology refers to the technology whereby cervical cells are suspended in a liquid transport 
medium and then displayed on a glass slide in the laboratory. Liquid-based cytology 
improves specimen adequacy by minimizing artifact, such as inflammation, non-cellular 
debris, and epithelial cell clumping, which may obscure interpretation of the smear. 
However, while the uniform cell layer from liquid-based cytology allows for easier 
interpretation, pathologists and cytotechnologists cannot use the additional information 
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provided by background inflammation as clues facilitating diagnosis. In addition, large 
systematic review challenged the clinical relevance of this difference in adequacy by failing 
to discover a difference in the number of unsatisfactory slides (65). One significant 
advantage conferred by liquid-based cytology is the ability to collect reflex HPV testing, 
which otherwise must be obtained by a separate sample in systems using conventional 
cytology.  
At the time liquid-based cytology was developed, the test was marketed as a more sensitive 
screening test than conventional cytology which was supported by early studies with clear 
methodological inadequacies (66-69). Recent studies have challenged this notion, and to 
date, the question remains largely unanswered (20, 70, 71). A systematic review of 56 
published studies that included over 1 million slides recently addressed the current 
literature on this subject (19). Regarding study design, no studies were noted to be “ideal” 
but five were considered to be of high-quality. The authors concluded that liquid-based 
cytology offered no improvement over conventional cytology for the detection of high-
grade lesions. Other systematic and independent reviews have reported similar findings (18, 
72). Observational data suggest that liquid-based samples may improve the detection of 
glandular lesions (73-75). 
Arguably, the liquid-based Pap screening test is not a “better” test than conventional 
cytology. However, despite the increased cost, the liquid-based screen offers advantages 
that will maintain its use in developed countries, particularly the United States. In the 2006 
screening guidelines, the American Society for Colposcopy and Cervical Pathology endorses 
reflex HPV testing as the preferred triage strategy for an ASCUS Pap result, which is 
supported by data from a large, well-designed clinical trial (37, 76). Therefore, given the ease 
of HPV testing with liquid-based samples and the current available infrastructure, the 
return of conventional cytology to the US is unlikely. However, should primary HPV 
screening with reflex cytology for positive results be adopted in the future, liquid based 
screening may become a less cost effective strategy given that the number of samples will 
decline. Importantly, the aforementioned studies support the use of conventional cytology 
as a safe, effective, and cost-effective screening strategy in settings with limited resources. 
11. Conclusions 
 The Pap smear is the single most successful cancer screening tool in modern medicine. 
 Cervical cancer is due to persistent infection with high-risk, oncogenic HPV strains. 
 Even in women with documented high-grade dysplasia (CIN 2 or greater), a long 
premalignant window exists which allows for purposeful intervention and prevention 
of progression to malignancy. 
 As a result, newer screening recommendations have decreased screening intervals to 
maximize the benefit of screening and decrease unnecessary interventions 
 As our understanding of HPV increases, Pap smear screening intervals continue to 
decline and triage strategies may change. It is imperative that practitioners remain 
informed of evidence-based guidelines.  
 Despite the availability of screening and preventative strategies, the majority of the 
cervical cancer disease burden is in the developing world. Inequalities in the availability 
of screening are a substantial public health challenge. 
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 Universal vaccination against HPV has the potential to substantially reduce the cervical 
cancer disease burden worldwide, however cost and other barrier currently limited the 
widespread adoption of this strategy. 
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